undamentalytics Newsletter

Sherman Mark Andrew: insider trades

Officer at Dolby Laboratories, Inc. No open-market purchases and 45 sales not made under a pre-set plan, reported from February 8, 2012 to December 19, 2023.

What happened after Sherman Mark Andrew’s sales?

After their sales, the shares moved −6.3% against the index over 12 months on average (a negative figure means selling was the right call); 56% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Sherman Mark Andrew: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 45 −0.8% −1.7% 60% 12 0.46 0.65 No reliable evidence
Sales, 12 months after the report 45 −6.3% −3.4% 56% 12 −1.30 0.22 No reliable evidence
Sales, 12 months after the trade 45 −6.9% −8.1% 60% 12 −1.46 0.17 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Dolby Laboratories, Inc. DLB EVP, Gen. Counsel & Secretary045February 8, 2012December 19, 2023

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
December 19, 2023December 18, 2023 DLB Sale $906,333 −13.7%−36.3%−34.1%
July 14, 2023July 12, 2023 DLB Sale $1,869,000 −5.4%−32.7%−37.3%
May 10, 2023May 8, 2023 DLB Sale $1,253,968 −16.8%−28.8%−27.3%
February 7, 2023February 3, 2023 DLB Sale $1,221,847 +0.9%−26.9%−28.5%
December 22, 2022December 20, 2022 DLB Sale $111,531 +16.9%+0.2%+0.6%
December 19, 2022December 16, 2022 DLB Sale $519,019 +17.6%+0.6%−3.4%
February 9, 2022February 9, 2022 DLB Sale $138,860 +7.2%+15.8%+17.4%
December 20, 2021December 17, 2021 DLB Sale $298,503 −13.5%−8.5%−8.1%
December 16, 2021December 16, 2020 DLB Sale $160,780 −15.7%−8.1%−25.7%
March 3, 2021March 1, 2021 DLB Sale $1,300,000 −12.6%−40.2%−38.1%
February 17, 2021February 16, 2021 DLB Sale $1,235,000 −2.8%−33.9%−32.7%
February 8, 2021February 5, 2021 DLB Sale $2,533,834 −3.6%−33.3%−33.4%
December 21, 2020December 18, 2020 DLB Sale $150,630 −1.7%−28.2%−26.5%
December 17, 2020December 16, 2020 DLB Sale $308,640 −0.4%−26.5%−25.7%
November 5, 2020November 3, 2020 DLB Sale $2,000,000 −2.9%−28.9%−26.8%
November 3, 2020November 2, 2020 DLB Sale $1,900,000 −1.3%−26.7%−25.4%
February 20, 2020February 19, 2020 DLB Sale $1,460,000 −7.8%+12.5%+12.4%
February 10, 2020February 6, 2020 DLB Sale $2,636,118 −8.2%+13.6%+10.6%
February 6, 2020February 5, 2020 DLB Sale $3,597,908 −6.5%+11.8%+10.8%
August 2, 2019July 31, 2019 DLB Sale $3,882,975 +5.9%+6.7%−8.4%
February 25, 2019February 21, 2019 DLB Sale $1,903,928 −4.9%−6.6%−9.1%
December 19, 2018December 18, 2018 DLB Sale $305,044 −10.4%−20.9%−19.7%
August 27, 2018August 23, 2018 DLB Sale $700,000 +5.1%−13.7%−15.2%
February 27, 2018February 26, 2018 DLB Sale $650,000 −3.6%−3.4%−1.8%
February 9, 2018February 7, 2018 DLB Sale $5,098,894 −2.9%−1.5%−1.7%
January 16, 2018January 12, 2018 DLB Sale $650,000 +11.0%+5.0%+2.7%
December 19, 2017December 18, 2017 DLB Sale $286,893 +5.6%+4.3%+6.9%
October 20, 2017October 18, 2017 DLB Sale $420,000 −3.2%+6.2%+6.8%
September 15, 2017September 13, 2017 DLB Sale $787,500 −0.8%+0.6%+3.0%
March 31, 2017March 29, 2017 DLB Sale $315,000 −8.1%+10.2%+9.2%
March 2, 2017March 1, 2017 DLB Sale $300,000 +1.8%+17.1%+15.9%
February 1, 2017January 30, 2017 DLB Sale $590,737 +2.4%+10.3%+10.2%
December 22, 2016December 22, 2016 DLB Sale $51,552 +7.8%+15.5%+15.6%
December 19, 2016December 16, 2016 DLB Sale $153,536 +7.4%+16.9%+16.5%
August 11, 2016August 11, 2016 DLB Sale $304,647 −4.8%−12.8%−12.1%
October 27, 2015October 26, 2015 DLB Sale $155,970 +10.5%+36.1%+41.1%
August 12, 2015August 12, 2015 DLB Sale $103,600 +1.8%+41.5%+42.3%
January 22, 2015January 22, 2015 DLB Sale $49,914 −1.0%−14.4%−13.9%
December 29, 2014December 24, 2014 DLB Sale $39,845 −12.0%−22.0%−20.6%
December 18, 2014December 17, 2014 DLB Sale $112,206 −13.9%−22.3%−23.7%
January 24, 2014January 23, 2014 DLB Sale $78,961 +0.6%−19.5%−18.7%
December 30, 2013December 26, 2013 DLB Sale $65,058 +13.4%−1.4%−0.5%
December 18, 2013December 18, 2013 DLB Sale $85,689 +16.7%+2.1%+0.3%
February 5, 2013February 1, 2013 DLB Sale $136,358 −6.2%+7.6%+6.2%
February 8, 2012February 7, 2012 DLB Sale $97,748 +15.2%−21.5%−20.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Sherman Mark Andrew traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.